JNCI Journal of the National Cancer Institute最新文献

筛选
英文 中文
Re: Association of immunoglobulin E levels with glioma risk and survival. 免疫球蛋白E水平与胶质瘤风险和生存的关系。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-03-01 DOI: 10.1093/jnci/djae344
George A Alexiou, Panagiota Zagorianakou, Spyridon Voulgaris
{"title":"Re: Association of immunoglobulin E levels with glioma risk and survival.","authors":"George A Alexiou, Panagiota Zagorianakou, Spyridon Voulgaris","doi":"10.1093/jnci/djae344","DOIUrl":"10.1093/jnci/djae344","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"567"},"PeriodicalIF":9.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to Liu and Zhang. 对刘和张的回应。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-03-01 DOI: 10.1093/jnci/djae325
Rong Xu
{"title":"Response to Liu and Zhang.","authors":"Rong Xu","doi":"10.1093/jnci/djae325","DOIUrl":"10.1093/jnci/djae325","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"564"},"PeriodicalIF":9.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RE: Glucagon-like peptide 1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data. RE:GLP-1受体激动剂和胰腺癌风险:使用真实世界数据的靶试验模拟。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-03-01 DOI: 10.1093/jnci/djae324
Xiaoxia Liu, Chongjie Zhang
{"title":"RE: Glucagon-like peptide 1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data.","authors":"Xiaoxia Liu, Chongjie Zhang","doi":"10.1093/jnci/djae324","DOIUrl":"10.1093/jnci/djae324","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"562-563"},"PeriodicalIF":9.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RE: Characteristics of a cost-effective blood test for colorectal cancer screening. 一种具有成本效益的结肠直肠癌筛查血液检测的特点。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-03-01 DOI: 10.1093/jnci/djae340
Qiang Hu, Xiyin Yang, Yuanshui Sun
{"title":"RE: Characteristics of a cost-effective blood test for colorectal cancer screening.","authors":"Qiang Hu, Xiyin Yang, Yuanshui Sun","doi":"10.1093/jnci/djae340","DOIUrl":"10.1093/jnci/djae340","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"570-571"},"PeriodicalIF":9.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gerotherapeutics: aging mechanism-based pharmaceutical and behavioral interventions to reduce cancer racial and ethnic disparities. 老年治疗:基于衰老机制的药物和行为干预,减少癌症的种族和民族差异。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-03-01 DOI: 10.1093/jnci/djae211
Jeanne S Mandelblatt, Michael H Antoni, Traci N Bethea, Steve Cole, Barry I Hudson, Frank J Penedo, Amelie G Ramirez, G William Rebeck, Swarnavo Sarkar, Ann G Schwartz, Erica K Sloan, Yun-Ling Zheng, Judith E Carroll, Mina S Sedrak
{"title":"Gerotherapeutics: aging mechanism-based pharmaceutical and behavioral interventions to reduce cancer racial and ethnic disparities.","authors":"Jeanne S Mandelblatt, Michael H Antoni, Traci N Bethea, Steve Cole, Barry I Hudson, Frank J Penedo, Amelie G Ramirez, G William Rebeck, Swarnavo Sarkar, Ann G Schwartz, Erica K Sloan, Yun-Ling Zheng, Judith E Carroll, Mina S Sedrak","doi":"10.1093/jnci/djae211","DOIUrl":"10.1093/jnci/djae211","url":null,"abstract":"<p><p>The central premise of this article is that a portion of the established relationships between social determinants of health and racial and ethnic disparities in cancer morbidity and mortality is mediated through differences in rates of biological aging processes. We further posit that using knowledge about aging could enable discovery and testing of new mechanism-based pharmaceutical and behavioral interventions (\"gerotherapeutics\") to differentially improve the health of cancer survivors from minority populations and reduce cancer disparities. These hypotheses are based on evidence that lifelong differences in adverse social determinants of health contribute to disparities in rates of biological aging (\"social determinants of aging\"), with individuals from minoritized groups experiencing accelerated aging (ie, a steeper slope or trajectory of biological aging over time relative to chronological age) more often than individuals from nonminoritized groups. Acceleration of biological aging can increase the risk, age of onset, aggressiveness, and stage of many adult cancers. There are also documented negative feedback loops whereby the cellular damage caused by cancer and its therapies act as drivers of additional biological aging. Together, these dynamic intersectional forces can contribute to differences in cancer outcomes between survivors from minoritized vs nonminoritized populations. We highlight key targetable biological aging mechanisms with potential applications to reducing cancer disparities and discuss methodological considerations for preclinical and clinical testing of the impact of gerotherapeutics on cancer outcomes in minoritized populations. Ultimately, the promise of reducing cancer disparities will require broad societal policy changes that address the structural causes of accelerated biological aging and ensure equitable access to all new cancer control paradigms.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"406-422"},"PeriodicalIF":9.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142086043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RE: Maximizing scarce colonoscopy resources: the crucial role of stool-based tests. 最大限度地利用稀缺的结肠镜资源:粪便检查的关键作用。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-02-28 DOI: 10.1093/jnci/djaf041
Jane A McElroy, Kevin D Everett
{"title":"RE: Maximizing scarce colonoscopy resources: the crucial role of stool-based tests.","authors":"Jane A McElroy, Kevin D Everett","doi":"10.1093/jnci/djaf041","DOIUrl":"https://doi.org/10.1093/jnci/djaf041","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to McElroy and Everett. 对麦克尔罗伊和埃弗雷特的回应。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-02-28 DOI: 10.1093/jnci/djaf042
Gloria Coronado, Carolyn Rutter
{"title":"Response to McElroy and Everett.","authors":"Gloria Coronado, Carolyn Rutter","doi":"10.1093/jnci/djaf042","DOIUrl":"https://doi.org/10.1093/jnci/djaf042","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study. 晚期黑色素瘤的机体成分和检查点抑制剂治疗结果:一项多中心队列研究。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-02-21 DOI: 10.1093/jnci/djaf039
Mark Schuiveling, Laurens S Ter Maat, Isabella A J Van Duin, Rik J Verheijden, Max F Troenokarso, Pim Moeskops, Joost J C Verhoeff, Sjoerd G Elias, Wouter A C Van Amsterdam, Femke Burgers, Franchette W P J Van Den Berkmortel, Marye J Boers-Sonderen, Martijn F Boomsma, Jan Willem De Groot, John B A G Haanen, Geke A P Hospers, Djura Piersma, Gerard Vreugdenhil, Hans M Westgeest, Ellen Kapiteijn, Mariette Labots, Wouter B Veldhuis, Paul J Van Diest, Pim A De Jong, Josien P W Pluim, Tim Leiner, Mitko Veta, Karijn P M Suijkerbuijk
{"title":"Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study.","authors":"Mark Schuiveling, Laurens S Ter Maat, Isabella A J Van Duin, Rik J Verheijden, Max F Troenokarso, Pim Moeskops, Joost J C Verhoeff, Sjoerd G Elias, Wouter A C Van Amsterdam, Femke Burgers, Franchette W P J Van Den Berkmortel, Marye J Boers-Sonderen, Martijn F Boomsma, Jan Willem De Groot, John B A G Haanen, Geke A P Hospers, Djura Piersma, Gerard Vreugdenhil, Hans M Westgeest, Ellen Kapiteijn, Mariette Labots, Wouter B Veldhuis, Paul J Van Diest, Pim A De Jong, Josien P W Pluim, Tim Leiner, Mitko Veta, Karijn P M Suijkerbuijk","doi":"10.1093/jnci/djaf039","DOIUrl":"https://doi.org/10.1093/jnci/djaf039","url":null,"abstract":"<p><strong>Introduction: </strong>The association of body composition with checkpoint inhibitor outcomes in melanoma is a matter of ongoing debate. In this study, we aim to investigate body mass index (BMI) alongside CT-derived body composition metrics in the largest cohort to date.</p><p><strong>Methods: </strong>Patients treated with first-line anti-PD1 ± anti-CTLA4 for advanced melanoma were retrospectively identified from 11 melanoma centers in The Netherlands. From baseline CT scans, five body composition metrics were extracted: subcutaneous adipose tissue index, visceral adipose tissue index and skeletal muscle index, density and gauge. These metrics were correlated in uni- and multivariable Cox proportional hazards analysis with progression-free, overall and melanoma-specific survival (PFS, OS and MSS).</p><p><strong>Results: </strong>A total of 1471 eligible patients were included. Median PFS and OS were 9.1 and 38.1 months, respectively. Worse PFS was observed in underweight patients (multivariable HR = 1.86, 95% CI 1.14-3.06). Furthermore, prolonged OS was observed in patients with higher skeletal muscle density (multivariable HR = 0.88, 95% CI 0.81-0.97) and gauge (multivariable HR = 0.61, 95% CI 0.82-0.998), whereas higher visceral adipose tissue index was associated with worse OS (multivariable HR = 1.12, 95% CI 1.04-1.22). No association with survival outcomes was found for overweight, obesity or subcutaneous adipose tissue.</p><p><strong>Discussion: </strong>Our findings suggest that underweight BMI is associated with worse PFS, whereas higher skeletal muscle density and lower visceral adipose tissue index were associated with improved OS. These associations were independent of known prognostic factors, including sex, age, performance status and extent of disease. No significant association between higher BMI and survival outcomes was observed.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Colon, colorectal and all cancer incidence increase in the Young due to appendix reclassification. 由于阑尾的重新分类,结肠,结直肠癌和所有癌症的发病率在年轻人中增加。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-02-19 DOI: 10.1093/jnci/djaf038
Archie Bleyer, Lynn A G Ries, Danielle B Cameron, Sara A Mansfield, Stuart E Siegel, Ronald D Barr
{"title":"Colon, colorectal and all cancer incidence increase in the Young due to appendix reclassification.","authors":"Archie Bleyer, Lynn A G Ries, Danielle B Cameron, Sara A Mansfield, Stuart E Siegel, Ronald D Barr","doi":"10.1093/jnci/djaf038","DOIUrl":"10.1093/jnci/djaf038","url":null,"abstract":"<p><strong>Introduction: </strong>Increases in colon and colorectal cancer incidence among adolescents and young adults (AYAs) have been reported progressively. Most of the increase may be due to an artifact caused by reclassifying appendiceal carcinoids/neuroendocrine tumor (NET) as malignant.</p><p><strong>Methods: </strong>Age-adjusted incidence and survival data were obtained from the Surveillance, Epidemiology, and End Results (SEER) SEER22 database.</p><p><strong>Results: </strong>In AYAs during 2000-2020, appendix cancer had an average annual percent change (AAPC) in incidence increase that in males was 3.7 times greater than the next most increasing cancer (AAPC12.8,95%CI: 10.9-14.6 vs AAPC3.4 [kidney] , 95%CI : 2.7-3.5) and correspondingly in females 2.9-fold greater (AAPC14.6,95%CI : 11.9-17.3 vs AAPC4.2 [pancreas], 95%CI : 3.6-4.8). From 2000-2009 to 2015-2020, appendix cancer incidence increased 17-,6.5-and 2.5-fold in children 0-14, AYAs 15-39, and adults 40-49 years of age, respectively. Carcinoid/NET accounted for 95%, 90% and 80% of appendix cancer increase in the three age groups, respectively. In 3,446 AYAs diagnosed during 2010-2020 with 'malignant' appendix NET, the 6-year cancer specific survival was 99.4% (95%CI , 99.0%to99.6%). From 2000-2009 to 2015-2020, colon carcinoma incidence in AYAs increased 61% with the appendix included, and only 11% with the appendix excluded.</p><p><strong>Conclusions: </strong>Reclassification of appendix NET/carcinoids as malignant has artifactually increased the incidence of colon, colorectum, and all cancer in children and AYAs. Appendix NET/carcinoids are rarely fatal in < 40 year-olds and should not be considered as cancer and included in colorectal cancer analyses. To the extent that the appendix artifact occurs in 40-49 year-olds, recommendations for starting colorectal cancer screening earlier may be affected..</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early identification of weight loss trajectories in advanced cancer and associations with survival. 早期识别晚期癌症患者的体重减轻轨迹及其与生存的关系。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-02-18 DOI: 10.1093/jnci/djaf030
Sophia Fuller, Stacey Alexeeff, Bette Caan, Marcus Dasilva Goncalves, Richard F Dunne, Tobias Janowitz, Mariam Jamal-Hanjani, Tilak K Sundaresan, Elizabeth M Cespedes Feliciano
{"title":"Early identification of weight loss trajectories in advanced cancer and associations with survival.","authors":"Sophia Fuller, Stacey Alexeeff, Bette Caan, Marcus Dasilva Goncalves, Richard F Dunne, Tobias Janowitz, Mariam Jamal-Hanjani, Tilak K Sundaresan, Elizabeth M Cespedes Feliciano","doi":"10.1093/jnci/djaf030","DOIUrl":"https://doi.org/10.1093/jnci/djaf030","url":null,"abstract":"<p><p>Consensus criteria to diagnose unintentional weight loss, a condition often termed cachexia that affects most patients with advanced cancer, are based on 6-month changes by which time intervention is often ineffective. Leveraging the large and diverse population in Kaiser Permanente Northern California's community oncology practice, we studied 8,338 patients with advanced lung, pancreatic, or colorectal cancers. We calculated weekly weight change measurements from 2-months pre- to 6-months post-diagnosis to identify 4 weight change trajectories (Gain, Stable, Moderate Loss, and Severe Loss) and associated these trajectories with survival. With high agreement, we classified patients into these trajectories after 3 months and found them to be prognostic; those classified in Moderate (HR = 1.55; 95%CI: 1.45-1.67) or Severe Loss (HR = 2.20; 95%CI: 2.01-2.41) at 3 months had significantly increased risk of death compared to the Stable trajectory. Weight loss at 3 months post-diagnosis can accurately classify deleterious weight trajectories, allowing for earlier clinical intervention.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信